+1.925.223.6233

 

13 Feb

Posted at 15:33h in News
0 Likes

- New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer - File Submission and Approval Based on Data from Phase 3 SELECT Study Published in New England Journal of Medicine on...

13 Feb

Posted at 15:14h in News
0 Likes

New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer File Submission and Approval Based on Data from Phase 3 SELECT Study Published in New England Journal of Medicine on February 12,...

02 Feb

Posted at 15:10h in News
0 Likes

WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ --Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated...

07 Sep

Posted at 13:03h in News
0 Likes

Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib) Tokyo, Japan, September 7, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a collaborative development agreement with SFJ Pharma Ltd. ("SFJ"), a wholly-owned...